Breaking World Pharma News

NIAID/GSK experimental Ebola vaccine appears safe, prompts immune response

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline (GSK), was tested at the NIH Clinical Center in Bethesda, Maryland.

Read more...

GSK statement on first phase 1 trial results of a candidate Ebola vaccine

GlaxoSmithKlineFirst results from a small phase 1 trial published yesterday in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the USA who received it.

Read more...

Vegetable oil ingredient key to destroying gastric disease bacteria

The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs School of Engineering developed LipoLLA, a therapeutic nanoparticle that contains linolenic acid, a component in vegetable oils.

Read more...

Another reason to be thankful: turkeys may be lifesavers

While the turkey you eat on Thursday will bring your stomach happiness and could probably kick-start an afternoon nap, it may also save your life one day. That's because the biological machinery needed to produce a potentially life-saving antibiotic is found in turkeys. Looks like there is one more reason to be grateful this Thanksgiving.

Read more...

Bristol-Myers Squibb and Five Prime Therapeutics announce exclusive clinical collaboration

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb's investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R).

Read more...

Muscle relaxant may be viable treatment for rare form of diabetes

A commonly prescribed muscle relaxant may be an effective treatment for a rare but devastating form of diabetes, researchers at Washington University School of Medicine in St. Louis report. The drug, dantrolene, prevents the destruction of insulin-producing beta cells both in animal models of Wolfram syndrome and in cell models derived from patients who have the illness.

Read more...

Only half of patients take their medications as prescribed

Here is what we know: If people take medications prescribed to them, they usually get better. But only about half of all patients prescribed medication take it according to directions. Here is what we don't know: We don't know how to get patients to take their medications, despite many studies looking at the issue.

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]